comprehens transpar view
potenti impact help eas
manag goe extra mile provid transpar comprehens view
potenti impact manag detail transpar framework
describ potenti rang impact pandem significantli
comprehens hope nearli eclips notabl highlight
compani report compani robust oper result continu
progress commit acceler develop manufactur covid-
vaccin remain track first-in-human trial septemb potenti
avail scale new guidanc contempl like signific impact
deferr elect surgeri improv although bounce-back
growth becom normal manag outlook roughli line
framework outlin sector report estim revis
publish april although pandem far situat ground
remain rapidli evolv believ jnj comprehens framework provid
reason rang potenti outcom base avail fact today help
reduc level uncertainti face compani univers
exposur elect end-market reiter outperform rate rais
target price
result exceed expect led pharma grew organ
sale organ vs cse led pharma
direct consist recent intra-quart analysi devic beat
dollar organ due deferr begin mid-march
expect continu given wide rang potenti impact
articul manag refer investor recent updat
interact framework help assess sensit sale ep variou
assumpt durat slowdown surgic capac recoveri defer surgeri
chang model made increment reduct sale ep
estim beyond line guidanc expect sale declin
organ revis ep estim
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
johnson johnson hold compani engag
 manufactur sale rang product health care
field oper compani organ busi segment
one-year valuat scenario base
ev/ebitda ebitda bil
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
 close
immunolog sale driven strong uptak stelara crohn diseas
tremfya psoriasi increas relat demand partial off-set
remicad due increas discounts/reb biosimilar competit
oncolog sale driven darzalex market growth share gain
 eu strong sale imbruvica strong sale share growth zytiga
eu aspac partial off-set lower sale due gener
competit launch uptak erleada partial off-set velcad
neurosci sale driven strength invega sustenna new
patient start partial off-set risperd consta gener competit concerta
manufactur risk lead vaccin candid begin immin
identifi lead vaccin candid march expect final select
master seed product june compani establish new vaccin
manufactur facil plan begin product risk immin remain
track start phase clinic trial earli septemb eu clinic
data expect year-end put vaccin avail emerg use author
earli
intervent solut sale cc growth driven atrial fibril
procedur growth coupl strong diagnost cathet sale new product
partial off-set net neg impact
orthopaed cc driven lower spine knee
hip trauma
surgeri sale cc driven lower gener surgeri
vision sale cc driven lower surgic contact
beauti sale primarili due neutrogena growth e-commerc
warehous club well hydroboost promot time strength emea
over-the-counter sale driven market growth
strong flu allergi season well overal share gain well competit
suppli disrupt ou market driven primarili due impact
stronger cough cold season emea aspac
babi sale declin due babi center divestitur sku ration
relat impact emea aspac partial off-set strength
addit detail takeaway
immunolog sale bil mil cc growth quarter
driven strong uptak stelara crohn diseas tremfya psoriasi well
expand indic simponi aria increas relat demand remicad
sale declin due increas discounts/reb biosimilar competit
infecti diseas sale mil mil cc strong sale
symtuza increas demand across portfolio partial off-set increas
competit prezista
neurosci sale bil mil cc paliperidon long-act
inject grew due increas new patient start strong persist partial off-set
cannib risperd
oncolog sale bil mil cc darzalex continu strong
market perform share gain eu imbruvica growth driven due
increas patient uptak global higher market share increas demand
relat longer scrip written lower sale zytiga result gener
competit partial off-set strong sale share growth eu aspac erleada
growth driven launch uptak along share gain non-metastat castration-
resist prostat cancer avail emea countri
pulmonari hypertens sale mil mil cc growth
driven continu strong sale opsumit uptravi result continu market
growth increas relat demand portfolio growth also impact
lower sale tracleer due gener competit cannib opsumit
cardiovascular/metabolism/oth sale bil mil cc
declin primarili driven xarelto due increas rebat includ channel mix
dynam partial off-set market growth increas demand due longer
scrip written segment also driven lower sale invokana due share loss
competit pressur lower sale biosimilar competit procrit
pharma segment also realiz estim net posit impact bp
salesy/i chg cc cg org cg salesy/i chg cc cg org us simponi metabolism/ charl martineau pm univers toronto april
intervent solut sale mil mil cc growth driven
atrial fibril procedur growth coupl strong diagnost cathet sale new
product partial off-set net neg impact bp
orthopaed sale bil mil cc hip sale mil
mil cc driven lower net neg impact
bp partial off-set jnj leadership posit anterior approach continu
strong demand primari stem acti enabl technolog kincis
surgic autom jointpoint navig knee sale mil
mil cc driven neg impact bp partial off-set
continu global uptak new product trauma sale mil mil
cc driven neg impact bp market soft
spine sale mil mil cc driven neg
impact bp base busi declin spine partial off-set ou
share growth sport led new product ortho price pressur continu impact
categori orthopaed compar spine declin adjust last
year pricing-rel true-up hip knee declin compar
neg vs flat respect trauma price improv compar
flat vs segment experienc estim neg impact bp
 market realiz largest dollar impact
total balanc neg impact split rel evenli asia pacif
surgeri sale bil mil cc advanc surgeri sale
driven endocutt flat led neg impact
bp competit pressur partial off-set growth
new product aspac biosurgeri flat driven growth new product off-set
neg impact bp gener surgeri driven asp divestitur
neg impact
vision sale bil mil cc driven net neg impact
bp contact lenses/oth sale mil mil
cc partial off-set double-digit growth daili dispos lens acuvu
oasi surgic sale mil mil cc primarili driven neg
impact bp competit pressur partial off-set new
medic devic portfolio also realiz estim neg impact bp
result procedur defer pandem partial off-set
stock primarili asia pacif anticip procedur ramp back
salesy/i chg cc cg org cg salesy/i chg cc cg org cg medic charl martineau pm univers toronto april
babi sale mil mil cc declin primarili due
babi center divestitur sku ration relat impact emea
aspac partial off-set strength aveeno babi
beauti sale bil mil cc growth primarili due
neutrogena growth e-commerc warehous club well hydroboost promot time
strength emea addit aveeno ogx saw higher market demand due
partial off-set declin due impact china japan
 segment also experienc posit impact bp due
oral sale mil mil cc growth primarili due market
growth listerin mouthwash due increas demand relat well new
over-the-counter sale bil mil cc growth due market
growth driven bp strong flu allergi season overal share gain
well competit suppli disrupt zarbe natur strength ou market growth
primarili due impact bp stronger cough cold season emea
aspac global over-the-counter busi benefit bp due
women sale mil mil cc growth segment
driven driven increas demand germani growth napkin
primarili latam
wound care/oth sale mil mil cc primarili due
market growth neosporin adhes bandag due increas demand relat
consum segment realiz net posit impact bp relat product store
pandem
salesy/i chg cc cg org cg salesy/i chg cc cg org estimate varianc charl martineau pm univers toronto april
guid reflect rang potenti impact
manag lower organ sale growth guidanc
equat report sale bil previou guidanc
bil ep guidanc reduc
pharma management expect pharma busi resili underscor
strength jnj pharma franchis said compani expect small
level disrupt associ delay diagnosi new patient start doctor
offic visit recent declin addit physician-administ
drug also slow infus center repurpos
treatment center stagger infus time fewer chair compli
social distanc practic
consum compani attribut strength consum pantri load
expect strength continu rest year given reduc
store traffic expect off-set higher e-commerc activ
management expect soft skin off-set upsid over-the-counter grow
medic devic compani expect medic devic continu impact
procedur deferr well hospit divert resourc toward covid-
devic impact expect sign stabil
recoveri around devic sale trauma stroke
critic surgeri consid non-deferr overal new guidanc assum
neg impact bil medic devic prior guidanc
major market itali franc germani spain russia
repres md sale management estim defer
procedur declin declin
stabil
china japan korea repres md sale management
expect elect procedur declin
row repres anoth md sale compani assum
defer procedur declin declin
stabil
figur impact medic devic
 op margin bp cse
sale net cog lower lower tax partial off-set non-
op incom deliv ep upsid rel estim consensu
effect tax rate quarter compar includ
estim tax expens transit provis swiss tax reform partial off-set
reorgan certain foreign subsidiari addit impact recent issu
regul associ tax reform
estimate bpop bpnon-op bpnet chg y/i charl martineau pm univers toronto april
chang model
decreas sale estim ep estim
reflect manag updat guidanc also made rel minor adjust
top-lin project decreas sale estim per year
figur chang model
valuat target price base ebitda multipl
previous estim ntm ebitda one-year forward bil unch risk
unexpect challeng pharma product pipelin setback macro challeng regard
drug price unexpect advers impact headlin risk relat litig regulatori
qualiti issu greater expect impact
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
